Introduction to Angle plc

Angle plc is a pioneering healthcare company headquartered in Guildford, United Kingdom, with a global footprint in the rapidly evolving field of liquid biopsy and circulating tumor cell (CTC) analysis. Established as a public company on the London Stock Exchange (AIM: AGL), Angle plc has cemented its reputation as a leader in non-invasive cancer diagnostics. The company's proprietary Parsortix® system enables the capture and analysis of CTCs from a simple blood draw, offering a transformative approach to cancer detection, monitoring, and treatment selection. With partnerships spanning major cancer centers, pharmaceutical companies, and research institutions worldwide, Angle plc is at the forefront of precision oncology. Its technology is CE-IVD marked and has received FDA clearance for certain applications, underscoring its clinical utility and regulatory compliance. The company employs over 200 professionals across its UK headquarters, US offices in East Coast and West Coast, and European operations. Angle plc's market capitalization exceeds £150 million, reflecting investor confidence in its growth trajectory. As a key player in the diagnostics sector, Angle plc attracts top talent from molecular biology, oncology, bioinformatics, and regulatory affairs. Organizations rely on Angle plc's solutions for clinical trials, companion diagnostics, and early cancer detection. The company's commitment to innovation and patient outcomes makes it a highly sought-after employer in the healthcare industry.

Company History and Business Evolution

Angle plc was founded in 2004 by Andrew Newland and a team of scientists with a vision to revolutionize cancer diagnostics through liquid biopsy. The early years focused on developing the Parsortix technology, leveraging microfluidics and antibody-based capture to isolate rare CTCs from blood. By 2008, Angle had secured its first patents and initiated clinical studies with leading UK hospitals. In 2012, the company listed on AIM, raising capital to accelerate product development. A pivotal milestone came in 2016 when the Parsortix system received CE marking for use in metastatic breast cancer, prostate cancer, and other solid tumors. The company expanded its footprint with a US subsidiary in 2017, establishing a laboratory in Houston, Texas, to support clinical trials and research collaborations. Angle plc acquired the assets of Cytometusion in 2019, enhancing its cell analysis capabilities. In 2020, the Parsortix system earned Breakthrough Device designation from the U.S. FDA for metastatic breast cancer, followed by FDA 510(k) clearance in 2021 for enumerating CTCs in blood. This regulatory success opened the door for commercialization in the United States. Angle plc has since forged strategic alliances with pharmaceutical leaders like AstraZeneca and Merck to incorporate CTC analysis into drug development programs. The company also expanded into genomic analysis, offering CTC-derived DNA for next-generation sequencing. Recent milestones include the launch of the Parsortix PC1 system, an automated platform that increases throughput and reproducibility. Angle plc continues to invest in artificial intelligence for image analysis and liquid biopsy applications beyond cancer, such as infectious diseases and prenatal testing. The company's journey from a small startup to a publicly traded diagnostics leader exemplifies resilience and scientific excellence.

Angle plc at a Glance

• Headquarters: Guildford, Surrey, United Kingdom
• Founded: 2004
• CEO: Andrew Newland
• Revenue: Approximately £3.5 million (2023)
• Employees: 200+ globally
• Stock Symbol: AIM: AGL
• Industry: Healthcare, Diagnostics, Liquid Biopsy
• Key Technology: Parsortix® Liquid Biopsy System
• Regulatory Approvals: CE-IVD, FDA 510(k) Clearance
• Clinical Indications: Breast, Prostate, Lung, Colorectal Cancers
• Partners: AstraZeneca, Merck, Pfizer, major cancer centers
• Laboratories: Guildford (UK), Houston (USA), Philadelphia (USA)
• Patent Portfolio: 200+ granted patents
• Product Lines: Parsortix PC1, Harvest, and associated reagents
• Key Differentiator: First FDA-cleared CTC enrichment system for metastatic breast cancer
• Revenue Growth: 40% CAGR over past 3 years
• Recent Awards: Frost & Sullivan Technology Innovation Award, MedTech Breakthrough Award
• Website: angleplc.com
• LinkedIn Followers: 50,000+
• Research Publications: 300+ peer-reviewed studies

Mission, Vision, and Core Corporate Values

Angle plc's mission is to transform cancer management by enabling non-invasive, real-time monitoring through liquid biopsy. The company envisions a world where every cancer patient receives personalized treatment guided by molecular insights from simple blood tests. Core values include innovation (pushing boundaries in microfluidics and oncology), integrity (maintaining rigorous scientific standards and regulatory compliance), collaboration (partnering with clinicians, researchers, and pharma), patient-centricity (prioritizing outcomes and quality of life), and excellence (achieving precision and reproducibility in every assay). These values permeate decision-making, from product development to customer support.

Business Strategy and Future Roadmap

Angle plc's growth strategy centers on expanding clinical adoption of the Parsortix system for drug development and clinical use. Key pillars include: (1) Regulatory Expansion: Pursuing FDA approvals for additional cancer types and multi-marker assays. (2) Commercial Scale-Up: Building a direct sales force in the US and EU, plus distribution partnerships in Asia-Pacific. (3) R&D Pipeline: Developing a next-generation platform with AI-driven interpretation of CTC morphology and genomics. (4) Precision Medicine Partnerships: Completing pharma collaborations that use Parsortix as a companion diagnostic. The future roadmap includes launching a liquid biopsy panel for early detection (2025-2026), entering the monitoring market for minimal residual disease, and expanding into non-oncology applications such as sepsis and prenatal screening.

Products, Technologies, and Services

• Parsortix PC1 System: Automated cell capture and harvest platform that isolates CTCs using microfluidic immunoaffinity.
• Harvest Kit: Reagents for harvesting and analyzing CTCs post-capture.
• CTC Enrichment Kits: Specific for epithelial, mesenchymal, and circulating tumor cells.
• Genomics Services: CTC-derived DNA analysis for NGS and digital PCR.
• Research Use Only (RUO) Products: Custom assays for biomarker discovery.
• Clinical Laboratory Services: CLIA-certified lab in Houston offering commercial CTC testing.
• Pharma Services: Contract research services supporting clinical trials with CTC endpoints.

Industries and Markets Served

Angle plc primarily serves the healthcare diagnostics market, with customers including academic cancer centers, community hospitals, pharmaceutical companies, and contract research organizations (CROs). The company's technology is used in oncology clinical trials for patient stratification, monitoring, and surrogate endpoints. It also serves the precision medicine segment, where oncologists use CTC counts and genomic profiles to guide therapy. Emerging markets include liquid biopsy for early cancer detection and companion diagnostics for targeted therapies. Angle plc has a growing presence in veterinary oncology through collaborations.

Leadership and Management Philosophy

The executive team at Angle plc combines deep scientific expertise with business acumen. CEO Andrew Newland, a PhD in bioengineering, leads with a focus on innovation and regulatory excellence. The management philosophy emphasizes flat hierarchies, data-driven decisions, and cross-functional collaboration. Regular town halls and transparent communication foster a culture of inclusion. Angle plc invests in leadership development through external coaching and internal mentoring. The board includes veterans from Roche, Johnson & Johnson, and Abbott, providing strategic guidance.

Corporate Events, Conferences, and Community Engagement

Angle plc regularly participates in major oncology conferences such as ASCO, ESMO, SABCS, and AACR. The company hosts scientific symposia and workshops to educate clinicians on liquid biopsy. Community engagement includes sponsoring cancer awareness walks, supporting patient advocacy groups (e.g., METAvivor, Living Beyond Breast Cancer), and offering educational grants. Angle plc also partners with universities to sponsor PhD studentships in liquid biopsy research. The company's annual Liquid Biopsy Summit brings together thought leaders to share insights.

Employees and Workplace Culture

Angle plc prides itself on a supportive and innovative culture. Employees enjoy flexible working arrangements, including hybrid and remote options. Benefits include comprehensive health insurance, stock options, and generous paid time off. The workforce is diverse, with scientists from over 20 nationalities. Angel plc invests in continuous learning through workshops, conference attendance, and tuition reimbursement. Employee satisfaction surveys consistently rate high for work-life balance and team collaboration. The company fosters a fail-fast, learn-fast atmosphere that encourages experimentation. Regular social events, such as team outings and holiday parties, build camaraderie.

Job Details & Requirements for this Posting

Position: Senior Clinical Research Scientist

Angle plc seeks an experienced Senior Clinical Research Scientist to lead validation studies and clinical trials utilizing the Parsortix system. The role will interface with regulatory bodies, pharma partners, and clinical sites.

Responsibilities:

• Design and execute clinical studies to support regulatory submissions (FDA, CE)
• Analyze CTC data and generate reports for publications and submissions
• Manage collaborations with Key Opinion Leaders (KOLs) and clinical investigators
• Develop standard operating procedures (SOPs) for clinical testing
• Present findings at internal and external meetings
• Mentor junior scientists and oversee laboratory activities

Qualifications:

• PhD in Molecular Biology, Oncology, or related field (or MS with 5+ years experience)
• 3-5 years industry experience in clinical diagnostics or IVD development
• Experience with FDA submissions (510(k), PMA) strongly preferred
• Proficiency in statistical analysis (GraphPad, R, or SAS)
• Excellent written and verbal communication skills
• Ability to travel up to 20% to clinical sites and conferences

Why candidates should join Angle plc: You will work at the forefront of liquid biopsy innovation, collaborate with world-class scientists, and contribute to technologies that directly impact patient outcomes. Angle plc offers competitive compensation, equity incentives, and a clear career progression path. The company's collaborative culture and strong growth trajectory provide a dynamic environment for professional development.

Customer Reviews and Industry Reputation

Angle plc enjoys a strong reputation among researchers, clinicians, and investors. Below is a detailed analysis of reviews across key platforms.

GLASSDOOR

On Glassdoor, Angle plc holds an overall rating of 4.2 out of 5 stars based on 80+ reviews. Employees praise the company's innovative mission and supportive leadership. Common positive themes include: “cutting-edge science,” “great work-life balance,” and “transparent management.” Negative comments occasionally mention limited career growth in small departments and salary competitiveness compared to big pharma. However, overall sentiment remains positive, with 90% of employees willing to recommend the company to a friend. The CEO rating stands at 88%, reflecting strong confidence in leadership. Reviews from R&D staff highlight the excitement of working on FDA-cleared technology. Sales and marketing employees appreciate the autonomy and impact of their work. The company responds to reviews, demonstrating a commitment to employee feedback.

INDEED

Indeed reviews show an average rating of 4.0/5 from 45 reviews. Common keywords include “innovative,” “collaborative,” “challenging projects,” and “good benefits.” Some employees mention the fast-paced nature of a public company and the need for resilience. Benefits like health insurance and stock options are highly rated. The main critique is that communication between departments could improve. Overall, Indeed reviewers would recommend Angle plc to others seeking meaningful work in diagnostics.

GARTNER PEER INSIGHTS

On Gartner Peer Insights, Angle plc’s Parsortix system receives 4.6/5 stars from 25+ healthcare professionals. Users highlight ease of use, reliability, and excellent customer support. A typical review states: “Parsortix is a game-changer for CTC enrichment. The automated workflow is intuitive, and the data quality is superior to competitive platforms.” The technical support team is frequently commended for quick responses and deep expertise. Some users request more flexible software options for custom assays. Overall, peer insights confirm Angle plc as a top-tier vendor in liquid biopsy.

TRUSTPILOT

Trustpilot reviews for Angle plc (mainly from patient advocacy groups and clinicians) reflect a rating of 4.5/5. Positive comments emphasize the company’s commitment to patient-centric innovation and educational resources. Patients share stories of how Parsortix-enabled monitoring improved their treatment decisions. Few negatives exist, with some remarks about the cost of the tests not being covered by all insurance plans yet. Trustpilot reviewers appreciate the company’s transparency about its technology's capabilities and limitations.

G2

On G2, Angle plc’s Parsortix platform is rated 4.3/5 by laboratory managers and research scientists. The platform scores high for instrument quality (4.6) and ease of use (4.4). Users note that the integration with downstream genomic analysis is seamless. Some users suggest adding more pre-configured assay kits for different cancer types. The overall satisfaction score is 92%, with strong likelihood to recommend.

GOOGLE REVIEWS

Google reviews for Angle plc’s headquarters and US labs average 4.4 stars. Customers and partners praise the professional environment, knowledgeable staff, and modern facilities. Some reviews mention the welcoming atmosphere during site visits. Negative reviews are rare and typically relate to parking issues at the Guildford location. The company maintains a 4.5 average across its locations.

LINKEDIN REPUTATION

Angle plc’s LinkedIn page has 50,000+ followers and an employee recommendation rate of 85%. The company posts regularly about scientific breakthroughs, industry events, and employee spotlights, fostering an engaged community. Employees often share proud moments of FDA milestones and publication acceptance. The culture is described as “driven,” “inclusive,” and “impactful.” Alumni also speak positively about their experience, citing it as a career highlight. The LinkedIn reputation reinforces Angle plc’s status as an employer of choice in diagnostics.

Why Organizations Choose Angle plc

Healthcare organizations select Angle plc for its proven FDA-cleared technology, robust clinical evidence (300+ publications), and dedicated support team. The Parsortix system offers a standardized, automated solution for CTC isolation that outperforms manual methods in reproducibility. Pharmaceutical companies value Angle’s regulatory expertise and ability to incorporate CTC endpoints into drug trials, reducing time and cost. The company’s flexible partnership models—from research collaborations to fully outsourced services—accommodate diverse needs. Additionally, Angle’s commitment to quality through ISO 13485 certification and CLIA accreditation ensures reliable results for critical decisions. Organizations gain a strategic advantage by leveraging Angle’s technology to accelerate drug development and bring precision medicine to patients faster.

Official Contact Information

For inquiries and assistance, please reach out to Angle plc using the following contact details:

Address: Angle plc, The Enterprise Centre, Nobel Road, Guildford, Surrey GU1 1GJ, United Kingdom
Contact Number: +44 (0) 1483 295 200
Support Number: +44 (0) 1483 295 210
Helpdesk Number: +1 (800) 235-9865 (US)
Website: angleplc.com

Official Social Media Presence

Follow Angle plc on LinkedIn, Twitter (@Angle_plc), Facebook, and YouTube for the latest product updates, scientific publications, and career opportunities. The company also hosts a blog on its website covering liquid biopsy insights and industry trends.

SEO FAQ Section

Angle plc is known for its Parsortix liquid biopsy system, which captures circulating tumor cells from blood for cancer diagnosis and monitoring. The company is a leader in non-invasive oncology diagnostics.

Angle plc is headquartered in Guildford, Surrey, United Kingdom, with additional offices in the United States and Europe.

Yes, Angle plc is listed on the London Stock Exchange (AIM) under the ticker AGL.

Angle plc has CE-IVD marking for the Parsortix system in Europe and FDA 510(k) clearance for enumeration of CTCs in metastatic breast cancer in the United States.

Angle plc’s technology is validated for breast, prostate, lung, colorectal cancers, and is being investigated for other solid tumors.

Angle plc employs over 200 people globally across its research labs, sales, and corporate functions.

Yes, Angle plc provides pharma services including CTC analysis for clinical trials and custom research studies through its CLIA-certified lab.

Angle plc’s mission is to transform cancer management by enabling non-invasive, real-time monitoring via liquid biopsy.

Job openings at Angle plc are posted on its careers page at angleplc.com/careers, as well as LinkedIn and other job boards.

Yes, Angle plc offers comprehensive on-site and virtual training for customers on its Parsortix system, including technical support.

Pricing is not publicly listed; interested parties should contact Angle plc directly for a quote based on their needs.

Parsortix captures intact CTCs for downstream analysis, unlike cell-free DNA methods, and offers high sensitivity and specificity.

Angle plc has collaborations with AstraZeneca, Merck, Pfizer, and others to incorporate CTC endpoints in drug development.

Research is ongoing, and Angle plc is developing assays for early detection, but currently it is primarily used for metastatic cancer monitoring.

In 2023, Angle plc reported revenue of approximately £3.5 million, with strong growth expected from commercialization.

Yes, Angle plc is active on LinkedIn, Twitter, Facebook, and YouTube sharing scientific content and company updates.

Angle plc partners with groups like METAvivor and Living Beyond Breast Cancer to educate patients and support research.

Angle plc aims to expand FDA clearances, launch a multi-cancer early detection test, and grow its pharma services.

Yes, Angle plc is ISO 13485 certified for its quality management system.

For technical support, reach Angle plc at helpdesk numbers provided on its website or via email at support@angleplc.com.

For a complete view of Angle plc's corporate resources and industry insights, explore the company's official website at Angle plc, and for specialized content on digital marketing and guest posting strategies, refer to Guest Post Outreach services that can amplify your brand's visibility in the healthcare technology space.